Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine

Advanced Drug Delivery Reviews

Volumn 56, Issue 6, 2004, Pages 835-852

  Crotty, Shane ^a,b   Andino, Raul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

AIDS; HIV; Mucosal vaccine; Poliovirus; Sabin; SIV; Vaccine vector

Indexed keywords

ANTIGENS; DISEASE CONTROL; GENES; IMMUNIZATION; IMMUNOLOGY; VECTORS; VIRUSES;

HUMAN IMMUNODEFICIENY VIRUS (HIV); POLIVIRUS VACCINE STRAINS; SYSTEMIC IMMUNE RESPONSES; VACCINE VECTORS;

VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; ANTIGENICITY; CELLULAR IMMUNITY; CORRELATION ANALYSIS; DISEASE COURSE; GENE SEQUENCE; GENOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INOCULATION; MONKEY; MOUSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SEROLOGY; SERUM; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 1942451743     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.042     Document Type: Article

References (62)

1. Bledsoe A.W., Jackson C.A., McPherson S., Morrow C.D. Cytokine production in motor neurons by poliovirus replicon vector gene delivery. Nat. Biotechnol. 18:2000;964-969.
2. Gromeier M., Lachmann S., Rosenfeld M.R., Gutin P.H., Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA. 97:2000;6803-6808.
3. Fecci P.E., Gromeier M., Sampson J.H. Viruses in the treatment of brain tumors. Neuroimaging Clin. North Am. 12:2002;553-570.
4. UNAIDS, WHO. Report on the Global HIV/AIDS Epidemic. 2001;World Health Organization, Geneva.
5. Miller C.J., Alexander N.J., Vogel P., Anderson J., Marx P.A. Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J. Med. Primatol. 21:1992;64-68.
6. Miller C.J., Vogel P., Alexander N.J., Sutjipto S., Hendrickx A.G., Marx P.A. Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am. J. Pathol. 141:1992;655-660.
7. Sewell A.K., Price D.A. Dendritic cells and transmission of HIV-1. Trends Immunol. 22:2001;173-175.
8. Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K.A., Reimann K.A., Reinhart T.A., Rogan M., Cavert W., Miller C.J., Veazey R.S., Notermans D., Little S., Danner S.A., Richman D.D., Havlir D., Wong J., Jordan H.L., Schacker T.W., Racz P., Tenner-Racz K., Letvin N.L., Wolinsky S., Haase A.T. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 286:1999;1353-1357.
9. Miller C.J., Lu F.X. Anti-HIV and -SIV immunity in the vagina. Int. Rev. Immunol. 22:2003;65-76.
10. Miller C.J., Shattock R.J. Target cells in vaginal HIV transmission. Microbes Infect. 5:2003;59-67.
11. Hu J., Gardner M.B., Miller C.J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:2000;6087-6095.
12. Weiss R.A. How does HIV cause AIDS? Science. 260:1993;1273-1279.
13. Lifson J.D., Martin M.A. One step forwards, one step back. Nature. 415:2002;272-273.
14. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
15. Letvin N.L., Barouch D.H., Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20:2002;73-99.
16. Crotty S., Lohman B.L., Lu F.X., Tang S., Miller C.J., Andino R. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J. Virol. 73:1999;9485-9495.
17. Crotty S., Miller C.J., Lohman B.L., Neagu M.R., Compton L., Lu D., Lu F.X., Fritts L., Lifson J.D., Andino R. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75:2001;7435-7452.
18. Ogra P.L. Mucosal Immunology. 2nd ed. 1999;Academic Press, San Diego.
19. Sutter R.W., Cochi S.L., Melnick J.L. Live attenuated poliovirus vaccines. Orenstein W. Vaccines. 3rd ed. 1999;1230 W.B. Saunders, Philadelphia.
20. Heinz B.A., Rueckert R.R., Shepard D.A., Dutko F.J., McKinlay M.A., Fancher M., Rossmann M.G., Badger J., Smith T.J. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:1989;2476-2485.
21. Zhaori G., Sun M., Faden H.S., Ogra P.L. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J. Infect. Dis. 159:1989;1018-1024.
22. Faden H., Modlin J., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162:1990;1291-1297.
23. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., McMichael A.J. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
24. Sutjipto S., Pedersen N.C., Miller C.J., Gardner M.B., Hanson C.V., Gettie A., Jennings M., Higgins J., Marx P.A. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64:1990;2290-2297.
25. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210.
26. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
27. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
28. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
29. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
30. Yang O.O., Kalams S.A., Trocha A., Cao H., Luster A., Johnson R.P., Walker B.D. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:1997;3120-3128.
31. Yang O.O., Walker B.D. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv. Immunol. 66:1997;273-311.
32. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:1999;857-860.
33. Lohman B.L., Miller C.J., McChesney M.B. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J. Immunol. 155:1995;5855-5860.
34. Schmitz J.E., Veazey R.S., Kuroda M.J., Levy D.B., Seth A., Mansfield K.G., Nickerson C.E., Lifton M.A., Alvarez X., Lackner A.A., Letvin N.L. Simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in gastrointestinal tissues of chronically SIV-infected rhesus monkeys. Blood. 98:2001;3757-3761.
35. Stevceva L., Alvarez X., Lackner A.A., Tryniszewska E., Kelsall B., Nacsa J., Tartaglia J., Strober W., Franchini G. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J. Virol. 76:2002;11659-11676.
36. Nannini E.C., Okhuysen P.C. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr. Gastroenterol. Rep. 4:2002;392-398.
37. Andino R., Silvera D., Suggett S.D., Achacoso P.L., Miller C.J., Baltimore D., Feinberg M.B. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science. 265:1994;1448-1451.
38. Mandl S., Sigal L.J., Rock K.L., Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc. Natl. Acad. Sci. USA. 95:1998;8216-8221.
39. Ogra P.L., Karzon D.T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J. Immunol. 102:1969;1423-1430.
40. Ogra P.L., Ogra S.S. Local antibody response to poliovaccine in the human female genital tract. J. Immunol. 110:1973;1307-1311.
41. Paul J.R., Riordan J.T., Melnick J.L. Antibodies to three different antigenic types of poliomyelitis virus in sera from north Alaskan Eskimos. Am. J. Hyg. 54:1951;275-285.
42. WHO. WHO Expert Committee on Biological Standardization. 46th Report. World Health Organization Tech. Rep. Ser. 1998;1-90.
43. Mattion N.M., Reilly P.A., DiMichele S.J., Crowley J.C., Weeks-Levy C. Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J. Virol. 68:1994;3925-3933.
44. AFHS. AFHS Drug Information. 1998;American Society of Hospital Pharmacists: SilverPlatter International, Bethesda, MD. Pharmacists A.S.o.H., ed.
45. Minor P.D. Poliovirus. Ahmed R. Viral Pathogenesis. 1997;555-574 Lippincott-Raven, Philadelphia.
46. Racaniello V.R., Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 214:1981;916-919.
47. Racaniello V.R. Picornaviridae: the viruses and their replication. Howley P.M. Fields Virology. vol. 1:2001;685-722 Lippincott Williams and Wilkins, Philadelphia.
48. Yim T.J., Tang S., Andino R. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Virology. 218:1996;61-70.
49. Tang S., van Rij R., Silvera D., Andino R. Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J. Virol. 71:1997;7841-7850.
50. van Kuppeveld F.J., de Jong A., Dijkman H.B., Andino R., Melchers W.J. Studies towards the potential of poliovirus as a vector for the expression of HPV 16 virus-like-particles. FEMS Immunol. Med. Microbiol. 34:2002;201-208.
51. Sigal L.J., Crotty S., Andino R., Rock K.L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 398:1999;77-80.
52. Mueller S., Wimmer E. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J. Virol. 72:1998;20-31.
53. Lee S.G., Kim D.Y., Hyun B.H., Bae Y.S. Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system. J. Virol. 76:2002;1649-1662.
54. Hull H.F., Birmingham M.E., Melgaard B., Lee J.W. Progress toward global polio eradication. J. Infect. Dis. 175:(Suppl. 1):1997;S4-S9.
55. Nathanson N., Fine P. Virology. Poliomyelitis eradication - a dangerous endgame. Science. 296:2002;269-270.
56. Dove A.W., Racaniello V.R. The polio eradication effort: should vaccine eradication be next? Science. 277:1997;779-780.
57. Racaniello V.R. It is too early to stop polio vaccination. [comment] Bull. Who. 78:2000;359-360.
58. Crotty S., Hix L., Sigal L.J., Andino R. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J. Gen. Virol. 83:2002;1707-1720.
59. Mandl S., Hix L., Andino R. Pre-existing immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. [In Process Citation] J. Virol. 75:2001;622-627.
60. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J. Infect. Dis. 163:1991;1-6.
61. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J. Infect. Dis. 175:(Suppl. 1):1997;S228-S234.
62. O'Connor D.H., Allen T.M., Vogel T.U., Jing P., DeSouza I.P., Dodds E., Dunphy E.J., Melsaether C., Mothe B., Yamamoto H., Horton H., Wilson N., Hughes A.L., Watkins D.I. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:2002;493-499.